SEC Tracker
Get the app
XNCR · XBRL financial data

Xencor financial statements, every quarter

The same tables from 16 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (XNCR's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers59,16450,966*15,99723,90717,79652,793*32,73243,60820,99928,237*4,51651,221
Research and development64,93964,220*56,87361,53158,22651,056*58,57861,66554,36764,824*64,66971,905
General and administrative12,49315,478*13,78717,74614,76714,915*17,33715,11514,15117,041*17,70916,384
Total operating expenses77,43279,698*70,66079,27772,99365,971*75,91576,78068,51881,865*82,37888,289
Operating income (loss)(18,268)(28,732)*(54,663)(55,370)(55,197)(13,178)*(43,183)(33,172)(47,519)(53,628)*(77,862)(37,068)
Interest income5,0237,638*8,5487,6817,5378,164*7,5387,2486,5386,200*5,4594,800
Interest expense76,156*9,6769,2829,0268,659*8,6658,2437,6657,354*4,7007,352
Other income (expense)61,364*0(4)(10)64*(31)(17)(17)(8)*396434
Income tax expense (benefit)013,662*0001,617*367(250)02,387*280(190)
Net income (loss)(24,269)(26,147)*(73,440)(67,337)(46,288)(45,553)*(48,418)(30,825)(6,027)(6,653)*(128,916)(21,729)
Earnings per share, basic USD per share(0.40)(0.42)*(1.20)(1.09)(0.72)(0.62)*(0.66)(0.41)(0.08)(0.09)*(1.71)(0.29)
Earnings per share, diluted USD per share(0.40)(0.42)*(1.20)(1.09)(0.72)(0.62)*(0.66)(0.41)(0.08)(0.09)*(1.71)(0.29)
Weighted average shares, basic thousands of shares60,62261,789*61,21261,67664,02373,176*73,66774,27974,41374,585*75,24775,859
Weighted average shares, diluted thousands of shares60,62261,789*61,21261,67664,02373,176*73,66774,27974,41374,585*75,24775,859

Balance sheet

CSV

Fiscal quarters (XNCR's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents52,73353,79031,03430,76829,03140,87539,67544,44228,29154,07314,17044,663
Marketable securities412,827497,725460,367449,372435,043408,971381,021358,984358,493381,158370,207333,152
Accounts receivable55,00023,73922,18135,92325,87260,84937,78547,55421,80529,29912,00142,234
Prepaid and other current assets21,64418,13916,73024,58820,74818,97713,92021,73225,59222,78925,90424,527
Total current assets571,176635,603574,847568,922589,597577,601521,271513,150518,441599,821482,855523,213
Property and equipment, net68,03566,12463,54063,86862,40059,80058,80856,79154,58753,30851,49250,013
Right-of-use asset34,80733,99540,21139,52738,83138,34137,65037,04838,37137,59236,81535,986
Total assets778,430965,135896,850840,619999,904951,945904,689879,424868,811875,495736,846724,960
Accounts payable14,96713,91416,01115,83818,77016,75916,19118,5339,07910,8287,91912,648
Accrued liabilities24,47223,56413,49119,55725,40719,21716,06323,88428,10834,96034,25336,446
Total current liabilities53,04173,91571,07575,58790,81387,43288,43696,08386,48595,90773,45781,865
Long-term debt—161,772150,895140,826128,340115,159101,83794,73687,77676,48282,12477,537
Lease liability, non-current56,37959,02566,81067,15666,48965,33864,18464,55165,33164,73562,59661,295
Total liabilities109,420303,048297,116291,905293,978277,919264,815259,073243,495239,908221,213221,732
Accumulated deficit(445,271)(471,418)(544,858)(612,195)(658,483)(704,036)(752,454)(783,279)(789,306)(795,959)(924,875)(946,604)
Total stockholders' equity669,010661,750600,073550,498708,864677,611639,874620,351625,316635,587515,633503,228
Total liabilities and equity778,430965,135896,850840,619999,904951,945904,689879,424868,811875,495736,846724,960
Common shares outstanding (cover page) thousands of shares60,87561,12061,66361,83469,98270,46271,17171,32371,41073,33974,14274,353

Cash flows

CSV

Fiscal quarters (XNCR's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(24,269)(26,147)*(73,440)(67,337)(46,288)(45,553)*(48,418)(30,825)(6,027)(6,653)*(128,916)(21,729)
Stock-based compensation12,89614,697*11,42117,19012,33812,332*12,21310,73710,09210,185*9,5619,192
Depreciation and amortization3,140*3,228*3,0353,024*3,054*2,994*2,6932,653*2,589*2,577*2,5672,440*
Net cash from operating activities(27,281)*18,169*(56,859)(67,350)*(28,142)*(49,837)*(16,220)(36,369)*(30,817)*(51,711)*(67,628)(55,658)*
Purchases of property and equipment2,832*980*1323,026*1,275*1,664*1,444383*183*1,140*610538*
Net cash from investing activities45,326*(203,130)*32,31866,016*(163,458)*57,252*13,66840,476*14,668*71,173*26,67785,120*
Proceeds from issuing common stock—0*———0*———0*——
Net cash from financing activities356*186,020*1,7871,070*189,864*4,431*1,249662*0*6,321*9501,031*
Net change in cash18,401*1,059*(22,754)(264)*(1,736)*11,846*(1,303)4,769*(16,149)*25,783*(40,001)30,493*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Xencor59,622116,5202,642*75.0M— 10-QSep 30, 2026
Evolus41,70077,952(1,933)*66.2M7.7 quarters 10-QSep 30, 2026
Savara41,800not reported(29,747)*205.5M5.8 quarters 10-QJun 30, 2026
Opko Health384,03665,414(36,315)*742.5M10.8 quarters 10-QSep 30, 2026
Iovance Biotherapeutics110,76899,313(60,841)*453.0M4.9 quarters 10-QJun 30, 2026
Elite Pharmaceuticals39,41632,35510,0701.1B— 10-QJun 30, 2026
Trevi Therapeutics54,302not reported(17,429)*142.5M18.3 quarters 10-QJun 30, 2026
Stoke Therapeutics107,27111,255(62,686)*65.4M5.2 quarters 10-QSep 30, 2026
KalVista Pharmaceuticals213,76840,863(14,455)53.2M19.7 quarters 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.